Voxelotor
Brand names: Oxbryta · Active ingredient: Voxelotor
In short: OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) .
What is Voxelotor used for?
OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb) . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Voxelotor dosage
The recommended dosage of OXBRYTA is 1,500 mg orally once daily.
For pediatric patients 4 years to less than 12 years, select the appropriate product (OXBRYTA tablets or OXBRYTA tablets for oral suspension) based on patient's ability to swallow tablets and patient's weight.
The recommended dosage of OXBRYTA for pediatric patients 4 years to less than 12 years is shown in Table 1.
Body Weight | Recommended Dose (once daily)
40 kg or greater | 1,500 mg
20 kg to less than 40 kg | 900 mg
10 kg to less than 20 kg | 600 mg
The recommended dosage of OXBRYTA in adults and pediatric patients 12 years and older with severe hepatic impairment (Child Pugh C) is 1,000 mg orally once daily.
No dosage adjustment of OXBRYTA is required for patients with mild or moderate hepatic impairment
.
The recommended dosage of OXBRYTA in pediatric patients 4 years to less than 12 years with severe hepatic impairment (Child Pugh C) is described in Table 2.
No dosage adjustment of OXBRYTA is required for patients with mild or moderate hepatic impairment .
Body Weight | Recommended Dose (once daily)
40 kg or greater | 1,000 mg (two 500 mg tablets)or900 mg (three 300 mg tablets for oral suspension or three 300 mg tablets)
20 kg to less than 40 kg | 600 mg
10 kg to less than 20 kg | 300 mg
CYP3A4 Inducers
Avoid concomitant use of strong or moderate CYP3A4 inducers with OXBRYTA .
If concomitant use of strong CYP3A4 inducers is unavoidable, the recommended dosage of OXBRYTA is 2,500 mg orally once daily. If concomitant use of moderate CYP3A4 inducers is unavoidable, the recommended dosage of OXBRYTA is 2,000 mg orally once daily.
CYP3A4 Inducers
Avoid concomitant use of strong or moderate CYP3A4 inducers with OXBRYTA . If concomitant use of strong or moderate CYP3A4 inducers is unavoidable, see Table 3 for dosage.
Body Weight | Recommended Dose (once daily)
Concomitant Use of Strong CYP3A4 Inducers | Concomitant Use of Moderate CYP3A4 Inducers
40 kg or greater | 2,500 mg (five 500 mg tablets) or2,400 mg (eight 300 mg tablets for oral suspension or eight 300 mg tablets) | 2,000 mg (four 500 mg tablets) or2,100 mg (seven 300 mg tablets for oral suspension or seven 300 mg tablets)
20 kg to less than 40 kg | 1,500 mg | 1,200 mg
10 kg to less than 20 kg | 900 mg | 900 mg
Administer OXBRYTA orally, once daily with or without food. If a dose is missed, or not administered entirely, resume dosing the following day.
OXBRYTA may be given with or without hydroxyurea.
OXBRYTA 300 mg and 500 mg Tablets
Patients should swallow OXBRYTA tablets whole. Do not cut, crush, or chew the tablets. …
How to take Voxelotor — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Hypersensitivity Reactions
Advise patients that serious hypersensitivity reactions including DRESS may occur, and to notify their healthcare providers if they develop generalized rash, urticaria, shortness of breath, facial swelling, swelling around their eyes, lips, or tongue, fever, fatigue, muscle and/or joint pain, swollen glands, and eosinophilia . Inform patients that some severe hypersensitivity reactions may affect their internal organs (such as liver, kidneys, lungs) and their blood cells. Advise patients to stop OXBRYTA if a severe hypersensitivity reaction is suspected.
Breastfeeding
Advise women not to breastfeed while they are on OXBRYTA therapy .
Dosage and Administration
To avoid a dosing error from using the wrong formulation of OXBRYTA, strongly advise patients and caregivers to visually inspect the tablets to verify the correct formulation each time the prescription is filled .
Advise patients to:
•Store OXBRYTA at 20°C to 30°C (68°F to 86°F).
•Continue taking OXBRYTA every day for as long as their physician tells them. …
Warnings & precautions
Do not take this medicine if: OXBRYTA is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia .
Serious hypersensitivity reactions after administration of OXBRYTA have occurred in <1% of patients treated. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia .
Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in postmarketing experience with OXBRYTA . Patients who develop a combination of skin rash, fever, peripheral eosinophilia, and internal systemic organ involvement (e.g., hepatic, renal, pulmonary) while receiving OXBRYTA should undergo medical evaluation.
Advise patients of the signs and symptoms of severe hypersensitivity reactions, including DRESS. If hypersensitivity reactions occur, discontinue OXBRYTA and administer appropriate medical therapy. Do not reinitiate OXBRYTA in patients who experience these symptoms with previous use.
OXBRYTA administration may interfere with measurement of Hb subtypes (HbA, HbS, and HbF) by high-performance liquid chromatography (HPLC) . If precise quantitation of Hb species is required, chromatography should be performed when the patient has not received OXBRYTA therapy in the immediately preceding 10 days.
Voxelotor side effects
The following clinically significant adverse reaction is discussed in other sections of the labeling:
•Hypersensitivity Reactions .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults and Pediatric Patients 12 Years and Older
The safety of OXBRYTA was evaluated in the HOPE trial based on data from 88 patients with SCD who received OXBRYTA 1,500 mg and 91 patients who received placebo orally once daily . Seventy-four patients received OXBRYTA 1,500 mg once daily for ≥24 weeks, 65 patients for ≥48 weeks, and 63 patients completed the 72-week treatment period.
In patients who received OXBRYTA 1,500 mg once daily the median age was 24 years (range:12 to 59 years); 65% female; 66% Black or African American and 23% Arab/Middle Eastern; and 65% receiving hydroxyurea at baseline.
Serious adverse reactions occurred in 3% (3/88) of patients receiving OXBRYTA 1,500 mg, which included headache, drug hypersensitivity, and pulmonary embolism occurring in 1 patient each. Permanent discontinuation due to an adverse reaction (Grades 1-4) occurred in 5% (4/88) of patients who received OXBRYTA 1,500 mg.
Dosage modifications (dose reduction or dosing interruption) due to adverse reactions occurred in 14% (12/88) of patients who received OXBRYTA 1,500 mg. …
Drug interactions
Strong or Moderate CYP3A4 Inducers
Coadministration of strong or moderate CYP3A4 inducers may decrease voxelotor plasma and whole blood concentrations and may lead to reduced efficacy.
Avoid coadministration of OXBRYTA with strong or moderate CYP3A4 inducers. Increase the OXBRYTA dosage when coadministration with a strong or moderate CYP3A4 inducer is unavoidable .
Voxelotor increased the systemic exposure of midazolam (a sensitive CYP3A4 substrate) . Avoid coadministration of OXBRYTA with sensitive CYP3A4 substrates with a narrow therapeutic index. If concomitant use is unavoidable, consider dose reduction of the sensitive CYP3A4 substrate(s).
OXBRYTA administration may interfere with measurement of Hb subtypes (HbA, HbS, and HbF) by HPLC . If precise quantitation of Hb species is required, chromatography should be performed when the patient has not received OXBRYTA therapy in the immediately preceding 10 days.
About this medicine
OXBRYTA contains voxelotor, a hemoglobin S polymerization inhibitor. The chemical name of voxelotor is 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde with a molecular formula of C19H19N3O3 and a molecular weight of 337.4.
The chemical structure of voxelotor is:
Voxelotor is a white-to-yellow-to-beige compound in crystalline Form II of its free base. It is non-hygroscopic and highly soluble in common organic solvents such as acetone and toluene and insoluble in water.
OXBRYTA film-coated tablets for oral use contain either 300 mg or 500 mg of voxelotor. Both strengths of OXBRYTA film-coated tablets contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. In addition, the 500 mg tablet film coating contains: polyethylene glycol 3350, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide. The 300 mg tablet film coating contains: black and red iron oxide, polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3c557fac-29ec-483f-b691-8a935d4decc3. Read the full official label on DailyMed.